Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review

被引:3
作者
Li, Linlin [1 ]
Huang, Siyuan [1 ]
Qin, Liying [2 ]
Yan, Ningning [1 ]
Shen, Shujing [3 ]
Li, Xingya [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Acad Med Sci, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Radiotherapy, Zhengzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
NSCLC; epidermal growth factor receptor; L833V/H835L; aumolertinib; case report; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CANCER; OSIMERTINIB; GEFITINIB; AFATINIB; PATIENT; L833V; H835L;
D O I
10.3389/fphar.2023.1257592
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The deletion of exon 19 and the Leu858Arg mutation of exon 21 are the most frequently observed mutations in the epidermal growth factor receptor (EGFR) gene, and patients with these mutations have shown significant benefits from EGFR-tyrosine kinase inhibitors (TKIs). However, there exists a small subgroup of patients with uncommon/rare mutations of EGFR, including compound mutations, which display a high degree of heterogeneity in terms of clinical features and variable sensitivities to EGFR-TKIs. The understanding of these uncommon mutations and their response to targeted therapy is still unclear and requires further investigation.Case presentation: We presented a case of a never-smoking patient with lung adenocarcinoma and brain metastasis. Initially, she received chemotherapy plus immune checkpoint inhibitor as first-line therapy as no EGFR mutations were detected by amplification-refractory mutation system-polymerase chain reaction. However, disease progressed rapidly. Subsequently, next-generation sequencing was carried out and revealed a rare compound mutation, L833V/H835L, in exon 21 of EGFR. As a result, she was switched to second-line therapy with the third-generation TKI aumolertinib, which demonstrated good efficacy. The patient was evaluated for a remarkable progression-free survival of 18 months and an overall survival of 29 months.Conclusion: The present study supports that aumolertinib might be a good treatment option for advanced NSCLC patients with EGFR L833V/H835L mutation, particularly in patients with brain metastasis. Furthermore, conducting a comprehensive screening for gene mutations is crucial in effectively identifying potential oncogenic driver mutations and guiding mutation-targeted therapy decisions in clinical practice.
引用
收藏
页数:8
相关论文
共 38 条
  • [1] UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
    Bar, Jair
    Peled, Nir
    Schokrpur, Shiruyeh
    Wolner, Mirjana
    Rotem, Ofer
    Girard, Nicolas
    Nana, Frank Aboubakar
    Derijcke, Sofie
    Kian, Waleed
    Patel, Sandip
    Gantz-Sorotsky, Hadas
    Zer, Alona
    Moskovitz, Mor
    Metro, Giulio
    Rottenberg, Yakir
    Calles, Antonio
    Hochmair, Maximilian
    Cuppens, Kristof
    Decoster, Lynn
    Reck, Martin
    Limon, Dror
    Rodriguez, Estelamari
    Astaras, Christoforos
    Bettini, Adrienne
    Hafliger, Simon
    Addeo, Alfredo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (02) : 169 - 180
  • [2] Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors
    Chang, Lih-Chyun
    Lim, Chor-Kuan
    Chang, Lih-Yu
    Chen, Kuan-Yu
    Shih, Jin-Yuan
    Yu, Chong-Jen
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 119 : 77 - 86
  • [3] Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
    Cho, Jang Ho
    Lim, Sung Hee
    An, Ho Jung
    Kim, Ki Hwan
    Park, Keon Uk
    Kang, Eun Joo
    Choi, Yoon Hee
    Ahn, Mi Sun
    Lee, Myung Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [4] A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples
    Ellison, Gillian
    Donald, Emma
    McWalter, Gael
    Knight, Lucy
    Fletcher, Lynn
    Sherwood, James
    Cantarini, Mireille
    Orr, Maria
    Speake, Georgina
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2010, 29
  • [5] NGS Technologies as a Turning Point in Rare Disease Resea rch, Diagnosis and Treatment
    Fernandez-Marmiesse, Ana
    Gouveia, Sofia
    Couce, Maria L.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2018, 25 (03) : 404 - 432
  • [6] A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib
    Frega, Stefano
    Conte, PierFranco
    Fassan, Matteo
    Polo, Valentina
    Pasello, Giulia
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (05) : E63 - E64
  • [7] Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review
    Galli, Giulia
    Corrao, Giulia
    Imbimbo, Martina
    Proto, Claudia
    Signorelli, Diego
    Ganzinelli, Monica
    Zilembo, Nicoletta
    Vitali, Milena
    de Braud, Filippo
    Garassino, Marina Chiara
    Lo Russo, Giuseppe
    [J]. LUNG CANCER, 2018, 115 : 135 - 142
  • [8] Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTMEGFR V2 and NGS Technologies
    Garcia, Jessica
    Gauthier, Arnaud
    Lescuyer, Gaelle
    Barthelemy, David
    Geiguer, Florence
    Balandier, Julie
    Edelstein, Daniel L.
    Jones, Frederick S.
    Holtrup, Frank
    Duruisseau, Mickael
    Grolleau, Emmanuel
    Rodriguez-Lafrasse, Claire
    Merle, Patrick
    Couraud, Sebastien
    Payen, Lea
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2021, 25 (02) : 239 - 250
  • [9] Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Gen, Soei
    Tanaka, Ichidai
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Hashimoto, Naozumi
    [J]. BMC CANCER, 2022, 22 (01)
  • [10] Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing
    Goodwin, Daryn
    Rathi, Vivek
    Conron, Matthew
    Wright, Gavin M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : 1166 - 1175